3 of the Best Dividend Stocks to Buy in October 2026

The article highlights Pfizer (6.3% yield), Realty Income (6.1%), and ExxonMobil (2.5%) as income-oriented stocks, compared with the S&P 500’s 1.1% average yield. Pfizer’s 2026 revenue guidance is $60.5B–$62.5B versus $62.6B a year earlier, while its shares are down 35% over five years; Exxon shares are up about 37% this year alongside rising oil prices, and Realty Income is down 4% this year and about 18% over five years. The author presents the stocks as potential sources of income and relative stability, while noting Pfizer’s growth and patent concerns and Realty Income’s relatively high forward P/E of 34.

Analysis

The key distinction is what each yield is compensating investors for—not which yield is highest. For Pfizer, the market’s concern is a cash-flow replacement problem: patent expirations matter only if new products and cost actions fail to offset lost exclusivity. A low earnings multiple and headline yield are not evidence of dividend safety unless post-expiration free cash flow covers the payout. Verify the patent-by-patent revenue exposure, dividend coverage, and pipeline launch trajectory before treating weakness as mispricing.

ExxonMobil is the clearest portfolio hedge, but less attractive as a fresh momentum entry after a substantial run. Its payoff is conditional on crude staying firm; a de-escalation in Iran or weaker demand could unwind both earnings expectations and the inflation-hedge premium. The dividend may support the stock, but does not remove commodity downside.

Realty Income is primarily a rates-and-credit exposure, not a bond substitute with guaranteed stability. Its quoted forward P/E is a poor REIT valuation anchor; track funds available for distribution, debt costs, occupancy, and cap rates instead. Higher long-term yields or tenant stress could pressure the multiple and refinancing economics even if monthly distributions continue.

Near term, these names may attract income-oriented flows, but that can obscure very different risks. Over 1–3 months, crude and Treasury yields are the main catalysts; over 6–18 months, Pfizer’s revenue replacement and Realty Income’s financing costs matter more. The contrarian point: yield screens can make a concentrated, cyclical trio look diversified when all three depend on confidence in future cash distributions.

Key Decisions for Investors

• Do not buy the three as an equal-weight “safe income” basket. Treat XOM as a conditional energy/inflation hedge; avoid chasing it unless crude strength persists, and reassess if Iran-related supply risk recedes or oil weakens materially.
• Keep PFE on a valuation watchlist rather than buying solely for yield. Require evidence that post-patent cash-flow losses are being replaced and that free cash flow covers the dividend; a worsening revenue outlook or weaker coverage falsifies the recovery case.
• For O, use AFFO/available-for-distribution coverage, occupancy, debt maturities, and refinancing costs—not headline yield or forward P/E—as entry checks. Rising long-term Treasury yields or deteriorating tenant metrics would argue against adding.
• If seeking a relative-value expression, favor XOM over O only while crude and inflation risks are rising and long yields are stable; reverse that preference if oil risk premium fades while rates fall. Verify current prices, distributions, and company guidance before sizing.